Taiwan · Delayed Price · Currency is TWD Mycenax Biotech Company Description
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan.
The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production.
It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services.
It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers.
The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
| Country | Taiwan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 387 |
| CEO | Pei-Jiun Chen |
Contact Details
Address: No. 66, Shengyi 2nd Rd. Zhubei, 302041 Taiwan | |
| Phone | 886 3 667 0880 |
| Website | mycenax.com |
Stock Details
| Ticker Symbol | 4726 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004726005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pei-Jiun Chen Ph.D. | President Chief Executive Officer and Chairman |
| Liru Yeh | Assistant Vice President of Finance and Accounting Division |
| Wei-I Chou Ph.D. | Associate Vice President of Pharmaceutical Development Division |
| Chin-Hao Liang | Associate Vice President of Administration and Management Division |